Skip to content

Examination of Zinc, S-adenosylmethionine, and Combination Therapy Versus Placebo in Alcoholics

Alcohol Abuse, Oxidative Stress, and Zinc Deficiency in Lung Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01899521
Acronym
ExZACTO
Enrollment
113
Registered
2013-07-15
Start date
2013-05-01
Completion date
2017-07-31
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcoholism

Keywords

alcoholism, lung health, pulmonary, macrophage, zinc, SAMe, S-adenosylmethionine, alveolar

Brief summary

This is a randomized, placebo controlled trial of dietary zinc and S-adenosylmethionine (SAMe) in otherwise healthy alcoholic US Veterans. The primary goal is to determine if either dietary zinc or S-adenosylmethionine (SAMe) can augment lung immune defenses in alcoholics and thereby decrease the risk of lung injury and infection.

Detailed description

Alcohol abuse is a major burden on society and even more of a problem in the Veteran population. Chronic alcohol ingestion can have serious health consequences including pneumonia and acute lung injury, which can occur suddenly and without warning even in physically fit individuals without apparent signs of alcohol dependence. Therefore, it is vital for the health of our Veterans and indeed the entire population to identify effective treatments that can limit or even prevent these devastating consequences. The primary goal of this clinical research project is to determine if dietary zinc or supplements of the antioxidant S-adenosylmethionine (SAMe) can augment lung immune defenses in otherwise healthy alcoholics and thereby decrease the risk of lung injury and infection. There is already strong evidence from the investigators' experimental animal model that moderate daily alcohol ingestion for as little as six weeks causes oxidative stress and zinc deficiency in the lung. These derangements result insult in dysfunction of the alveolar macrophage, which is the resident immune cell, and predisposes animals to the development of pneumonia. Importantly, in this same animal model, the investigators found that adding either zinc or antioxidants to the diet prevents these problems and preserves lung health even during daily alcohol ingestion. This project will translate basic findings in the animal model to the clinical setting and determine whether or not zinc or SAMe supplements are effective in humans who pathologically consume alcohol. This project will enroll Veterans seen at the Atlanta Veterans Hospital in the Substance Abuse Treatment Program (SATP). Participants will be evaluated by undergoing a procedure to obtain samples of fluid from their lungs, measure zinc levels, redox potential, and assess how well their alveolar macrophages respond to bacteria (by determining phagocytic capacity). After completion of the initial evaluation, the participants will be randomized to receive standard treatment (placebo), zinc supplements, dietary SAMe, or the combination of zinc and SAMe for 14 days. All subjects will be evaluated for two weeks as they undergo treatment. At the end of this two week period, measurements of lung zinc, redox potential and macrophage function will be repeated and compared between the two groups. The hypothesis is that both dietary zinc and SAM supplements will improve the immune function of the alveolar macrophage. If this project is successful, it will lead to larger clinical trials to determine if either dietary zinc and/or SAMe supplements can be effective even in the acute clinical setting and improve outcomes in alcoholics who develop pneumonia or acute lung injury. Overall, both zinc and SAMe supplements are safe and inexpensive to provide, allowing these potential treatments to be easily implemented in the Veteran population as well as society in general. Given the significant burden of unhealthy alcohol use, the investigators need ways to limit the physical consequences of alcohol abuse while the investigators continue the efforts at public education and addiction treatment.

Interventions

PROCEDUREBronchoscopy

Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques.

DIETARY_SUPPLEMENTZinc sulfate 220 mg once daily
DIETARY_SUPPLEMENTS-adenosylmethionine 400 mg twice daily

Sponsors

VA Office of Research and Development
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-60 years * Active alcohol use disorder

Exclusion criteria

* Any active and uncontrolled medical problem(s) * Known zinc deficiency * Primary substance of abuse something other than alcohol * Current abnormal chest x-ray * HIV-positive * Any disorder of blood coagulation * Currently on medical treatment with anti-coagulants, including: * warfarin * heparin * direct thrombin inhibitors * anti-platelet agents (other than Aspirin) * Daily use of vitamins or other nutritional supplements (unless taking as treatment for alcohol use disorder) * Renal impairment (GFR \< 60) * Active bipolar disorder * Active Parkinson's disease * Current pregnancy * Contraindication to treatment with zinc or S-adenosylmethionine * Inability to give informed consent (i.e., limited cognitive capacity) * Non-English speaking

Design outcomes

Primary

MeasureTime frameDescription
Primary EndpointInitial bronchoscopy to second bronchoscopy (Initial bronchoscopy performed prior to treatment and second bronchoscopy done 2-3 weeks after starting treatment)Improvement in alveolar macrophage phagocytic index. Phagocytic index will be measured before and after treatment phase. Phagocytic index is calculated using isolated alveolar macrophages from the bronchoscopy procedure such that phagocytic index = (total number of engulfed cells/total number of counted macrophages) x (number of macrophages containing engulfed cells/total number of counted macrophages) x 100.

Secondary

MeasureTime frameDescription
Secondary EndpointInitial bronchoscopy to second bronchoscopy (Initial bronchoscopy performed prior to treatment and second bronchoscopy done 2-3 weeks after starting treatment)Improvement in alveolar macrophage intracellular zinc. Intracellular zinc will be measured before and after treatment phase using isolated alveolar macrophages. The units of measure are relative fluorescence units/cell (RFU/cell) and measured using confocal microscopy techniques.

Other

MeasureTime frameDescription
Secondary EndpointInitial bronchoscopy to second bronchoscopy (Initial bronchoscopy performed prior to treatment and second bronchoscopy done 2-3 weeks after starting treatment)Improvement in redox potential in the alveolar space. Redox potential will be measured before and after treatment phase using lavage fluid and blood plasma.

Countries

United States

Participant flow

Pre-assignment details

Participants are enrolled when they sign consent, however, only get randomized after completing first bronchoscopy procedure. Therefore, there were some participants who enrolled but never completed the procedure in order to be randomized into a group. This is the reason for the discrepancy in numbers.

Participants by arm

ArmCount
Placebo Zinc and Placebo SAMe
Placebo tablet of zinc sulfate once daily and placebo tablet of s-adenosylmethionine twice daily Bronchoscopy: Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques.
23
Active Zinc and Placebo SAMe
Zinc sulfate 220 mg once daily and placebo tablet of s-adenosylmethionine twice daily Bronchoscopy: Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques. Zinc sulfate 220 mg once daily
25
Placebo Zinc and Active SAMe
Placebo tablet of zinc sulfate once daily and s-adenosylmethionine 400 mg twice daily Bronchoscopy: Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques. S-adenosylmethionine 400 mg twice daily
25
Active Zinc and Active SAMe
Zinc sulfate 220 mg once daily and s-adenosylmethionine 400 mg twice daily Bronchoscopy: Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques. Zinc sulfate 220 mg once daily S-adenosylmethionine 400 mg twice daily
22
Total95

Baseline characteristics

CharacteristicTotalPlacebo Zinc and Placebo SAMeActive Zinc and Placebo SAMePlacebo Zinc and Active SAMeActive Zinc and Active SAMe
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
95 Participants23 Participants25 Participants25 Participants22 Participants
Age, Continuous48 years46 years47 years47 years51 years
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants1 Participants0 Participants1 Participants1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
92 Participants22 Participants25 Participants24 Participants21 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants0 Participants0 Participants0 Participants1 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
77 Participants17 Participants20 Participants21 Participants19 Participants
Race (NIH/OMB)
More than one race
7 Participants2 Participants3 Participants2 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
10 Participants4 Participants2 Participants2 Participants2 Participants
Region of Enrollment
United States
95 participants23 participants25 participants25 participants22 participants
Sex: Female, Male
Female
15 Participants2 Participants4 Participants5 Participants4 Participants
Sex: Female, Male
Male
80 Participants21 Participants21 Participants20 Participants18 Participants
Smoking Status
Non-smoker
37 Participants9 Participants10 Participants10 Participants8 Participants
Smoking Status
Smoker
58 Participants14 Participants15 Participants15 Participants14 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 230 / 250 / 250 / 22
other
Total, other adverse events
17 / 2321 / 2516 / 2516 / 22
serious
Total, serious adverse events
1 / 230 / 251 / 250 / 22

Outcome results

Primary

Primary Endpoint

Improvement in alveolar macrophage phagocytic index. Phagocytic index will be measured before and after treatment phase. Phagocytic index is calculated using isolated alveolar macrophages from the bronchoscopy procedure such that phagocytic index = (total number of engulfed cells/total number of counted macrophages) x (number of macrophages containing engulfed cells/total number of counted macrophages) x 100.

Time frame: Initial bronchoscopy to second bronchoscopy (Initial bronchoscopy performed prior to treatment and second bronchoscopy done 2-3 weeks after starting treatment)

ArmMeasureGroupValue (MEAN)Dispersion
Placebo Zinc and Placebo SAMePrimary EndpointPre-treatment PI13518 Phagocytic Index (PI)Standard Deviation 11677
Placebo Zinc and Placebo SAMePrimary EndpointPost-treatment PI16704 Phagocytic Index (PI)Standard Deviation 15412
Active Zinc and Placebo SAMePrimary EndpointPost-treatment PI23850 Phagocytic Index (PI)Standard Deviation 47703
Active Zinc and Placebo SAMePrimary EndpointPre-treatment PI15892 Phagocytic Index (PI)Standard Deviation 18961
Placebo Zinc and Active SAMePrimary EndpointPost-treatment PI10734 Phagocytic Index (PI)Standard Deviation 9709
Placebo Zinc and Active SAMePrimary EndpointPre-treatment PI10849 Phagocytic Index (PI)Standard Deviation 11087
Active Zinc and Active SAMePrimary EndpointPre-treatment PI15530 Phagocytic Index (PI)Standard Deviation 17627
Active Zinc and Active SAMePrimary EndpointPost-treatment PI13955 Phagocytic Index (PI)Standard Deviation 14511
Secondary

Secondary Endpoint

Improvement in alveolar macrophage intracellular zinc. Intracellular zinc will be measured before and after treatment phase using isolated alveolar macrophages. The units of measure are relative fluorescence units/cell (RFU/cell) and measured using confocal microscopy techniques.

Time frame: Initial bronchoscopy to second bronchoscopy (Initial bronchoscopy performed prior to treatment and second bronchoscopy done 2-3 weeks after starting treatment)

ArmMeasureGroupValue (MEAN)Dispersion
Placebo Zinc and Placebo SAMeSecondary EndpointPre-treatment Intracellular Zinc2816 RFU/cellStandard Deviation 2149
Placebo Zinc and Placebo SAMeSecondary EndpointPost-treatment Intracellular Zinc2710 RFU/cellStandard Deviation 1980
Active Zinc and Placebo SAMeSecondary EndpointPost-treatment Intracellular Zinc3510 RFU/cellStandard Deviation 2590
Active Zinc and Placebo SAMeSecondary EndpointPre-treatment Intracellular Zinc3410 RFU/cellStandard Deviation 2655
Placebo Zinc and Active SAMeSecondary EndpointPre-treatment Intracellular Zinc3883 RFU/cellStandard Deviation 2723
Placebo Zinc and Active SAMeSecondary EndpointPost-treatment Intracellular Zinc4327 RFU/cellStandard Deviation 3092
Active Zinc and Active SAMeSecondary EndpointPre-treatment Intracellular Zinc4174 RFU/cellStandard Deviation 3386
Active Zinc and Active SAMeSecondary EndpointPost-treatment Intracellular Zinc3103 RFU/cellStandard Deviation 2823
Other Pre-specified

Secondary Endpoint

Improvement in redox potential in the alveolar space. Redox potential will be measured before and after treatment phase using lavage fluid and blood plasma.

Time frame: Initial bronchoscopy to second bronchoscopy (Initial bronchoscopy performed prior to treatment and second bronchoscopy done 2-3 weeks after starting treatment)

ArmMeasureGroupValue (MEAN)Dispersion
Placebo Zinc and Placebo SAMeSecondary EndpointPre-treatment GSSG33.0 GSSG percentage (measure of oxidation)Standard Deviation 30.5
Placebo Zinc and Placebo SAMeSecondary EndpointPost-treatment GSSG28.9 GSSG percentage (measure of oxidation)Standard Deviation 29.2
Active Zinc and Placebo SAMeSecondary EndpointPost-treatment GSSG19.7 GSSG percentage (measure of oxidation)Standard Deviation 23.8
Active Zinc and Placebo SAMeSecondary EndpointPre-treatment GSSG28.0 GSSG percentage (measure of oxidation)Standard Deviation 29.2
Placebo Zinc and Active SAMeSecondary EndpointPre-treatment GSSG21.6 GSSG percentage (measure of oxidation)Standard Deviation 25.3
Placebo Zinc and Active SAMeSecondary EndpointPost-treatment GSSG20.5 GSSG percentage (measure of oxidation)Standard Deviation 26.8
Active Zinc and Active SAMeSecondary EndpointPre-treatment GSSG28.5 GSSG percentage (measure of oxidation)Standard Deviation 30.6
Active Zinc and Active SAMeSecondary EndpointPost-treatment GSSG33.5 GSSG percentage (measure of oxidation)Standard Deviation 35.2
Other Pre-specified

Secondary Endpoint

Improvement in alveolar macrophage granulocyte macrophage - colony stimulating factor (GM-CSF) receptor expression. GM-CSF receptor expression will be measured before and after treatment phase using isolated alveolar macrophages. The units of measure are relative fluorescence units/cell (RFU/cell) and measured using confocal microscopy techniques. Both alpha- and beta-subunits of the receptor will be measured.

Time frame: Initial bronchoscopy to second bronchoscopy (Initial bronchoscopy performed prior to treatment and second bronchoscopy done 2-3 weeks after starting treatment)

Population: The cells were not stained appropriately, so this secondary measure could not be completed because the results were not analyzable.

Other Pre-specified

Secondary Endpoint

Improvement in serum zinc level. Serum zinc will be measured before and after treatment phase by collecting blood plasma. The units of measure are mcg/dl.

Time frame: Initial bronchoscopy to second bronchoscopy (Initial bronchoscopy performed prior to treatment and second bronchoscopy done 2-3 weeks after starting treatment)

ArmMeasureGroupValue (MEAN)Dispersion
Placebo Zinc and Placebo SAMeSecondary EndpointPre-treatment Serum Zinc79.5 mcg/dlStandard Deviation 18.5
Placebo Zinc and Placebo SAMeSecondary EndpointPost-treatment Serum Zinc71.2 mcg/dlStandard Deviation 9.7
Active Zinc and Placebo SAMeSecondary EndpointPost-treatment Serum Zinc95.6 mcg/dlStandard Deviation 36.3
Active Zinc and Placebo SAMeSecondary EndpointPre-treatment Serum Zinc76.9 mcg/dlStandard Deviation 12
Placebo Zinc and Active SAMeSecondary EndpointPre-treatment Serum Zinc78.5 mcg/dlStandard Deviation 12.1
Placebo Zinc and Active SAMeSecondary EndpointPost-treatment Serum Zinc80.1 mcg/dlStandard Deviation 14.9
Active Zinc and Active SAMeSecondary EndpointPre-treatment Serum Zinc75.0 mcg/dlStandard Deviation 11
Active Zinc and Active SAMeSecondary EndpointPost-treatment Serum Zinc92.0 mcg/dlStandard Deviation 34.8

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026